University of California, Los Angeles Neuro-Oncology Program
Welcome,         Profile    Billing    Logout  
 3 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cloughesy, Timothy F
NCI-2018-02010, NCT03732352: 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Completed
2
12
US
Fludeoxyglucose F-18, 18FDG, FDG, fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Osimertinib, AZD-9291, AZD9291, Mereletinib, Tagrisso, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Jonsson Comprehensive Cancer Center, AstraZeneca
EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, TP53 Wt Allele
01/24
01/24
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT05664243: A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
4
US
Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells
In8bio Inc.
Glioblastoma
12/25
12/25
NCT02101905: Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Completed
1
29
US
Laboratory Biomarker Analysis, Lapatinib, GSK572016, GW 2016, GW 572016, GW-572016, GW2016, GW572016, Lapatinib Ditosylate, Tykerb, Pharmacological Study, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
10/21
10/24
NCT04201873: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Recruiting
1
40
US
Dendritic Cell Tumor Cell Lysate Vaccine, DC tumor cell lysate vaccine, dendritic cell-pulsed tumor cell lysate vaccine, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Placebo Administration, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI), Merck Sharp & Dohme LLC, Phase One Foundation, Oncovir, Inc.
Recurrent Glioblastoma
08/25
08/26
Filka, Emese
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT04201873: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Recruiting
1
40
US
Dendritic Cell Tumor Cell Lysate Vaccine, DC tumor cell lysate vaccine, dendritic cell-pulsed tumor cell lysate vaccine, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Placebo Administration, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI), Merck Sharp & Dohme LLC, Phase One Foundation, Oncovir, Inc.
Recurrent Glioblastoma
08/25
08/26
Medina-Torne, Sheila
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT04965597: Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

Recruiting
2
40
US
Treosulfan, Dihydroxybusulfan, Ovastat, Treosulphan, Tresulfon, Trecondi, Fludarabine Phosphate, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, 9H-purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl), Beneflur, Fludara, Fludarabine-5'-Monophosphate, SH T 586, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, Emthexat, Emtexate, Farmitrexat, Methotrexate LPF, Methylaminopterin, Methotrexatum, Metotrexato, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Lapine T-Lymphocyte Immune Globulin, Anti-Thymocyte Globulin Rabbit, Grafalon, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, rATG, Thymoglobulin, Antithymocyte globulin rabbit ATG, Imtix, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, peripheral stem cell support, Peripheral Stem Cell Transplant, peripheral stem cell transplantation, Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic Blood and Marrow Transplantation, Allogeneic BMT, Quality-of-Life Assessment, Quality of Life Assessment, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, Multi-Gated Acquisition Scan, MUGA Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Biological Sample Collection, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Computed Tomography, Computed Axial Tomography, CAT Scan, CT Scan
Fred Hutchinson Cancer Center, Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, National Heart, Lung, and Blood Institute (NHLBI)
Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
12/25
12/26
CSIDE, NCT03619551: Conditioning SCID Infants Diagnosed Early

Recruiting
2
64
Canada, US
Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS
Michael Pulsipher, MD
SCID
08/26
08/26
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Calendar Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL
Active, not recruiting
2
121
Europe, Canada, US
CTL019
Novartis Pharmaceuticals, Children's Oncology Group
B-Cell Acute Lymphoblastic Leukemia
10/27
10/27
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT05664243: A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
4
US
Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells
In8bio Inc.
Glioblastoma
12/25
12/25

Download Options